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Integration of viral DNA into the host chromosome is an obligatory step in retroviral replication and is
dependent on the activity of the viral enzyme integrase. To examine the influence of chromatin structure on
retroviral DNA integration in vitro, we used a model target comprising a 13-nucleosome extended array that
includes binding sites for specific transcription factors and can be compacted into a higher-ordered structure.
We found that the efficiency of in vitro integration catalyzed by human immunodeficiency virus type 1 (HIV-1)
integrase was decreased after compaction of this target with histone H1. In contrast, integration by avian
sarcoma virus (ASV) integrase was more efficient after compaction by either histone H1 or a high salt
concentration, suggesting that the compacted structure enhances this reaction. Furthermore, although site-
specific binding of transcription factors HNF3 and GATA4 blocked ASV DNA integration in extended nucleo-
some arrays, local opening of H1-compacted chromatin by HNF3 had no detectable effect on integration,
underscoring the preference of ASV for compacted chromatin. Our results indicate that chromatin structure
affects integration site selection of the HIV-1 and ASV integrases in opposite ways. These distinct properties
of integrases may also affect target site selection in vivo, resulting in an important bias against or in favor of
integration into actively transcribed host DNA.
Stable integration of viral DNA into a host cell’s genome is
an essential step in the replication of retroviruses. The process
is catalyzed by the viral enzyme integrase and establishes the
integrated viral DNA (the provirus) as a genetic component
that persists for the life of the cell. Because of this unique
property, retroviruses have important potential value as vec-
tors for gene therapy in the treatment of human disease (for a
review, see reference 27). However, many sites in host chro-
matin can be targets for retroviral DNA integration, and in-
sertion near or within a cellular gene may lead to inappropriate
expression of that gene. The occasional integration in the vi-
cinity of proto-oncogenes or tumor suppressor genes accounts
for the oncogenicity of several retroviral genera (13, 32), and
this possibility seriously limits the use of retroviral vectors for
gene therapy (32). Recent cell culture experiments with human
immunodeficiency virus type 1 (HIV-1) have revealed a bias
for integration into highly expressed genes, especially genes
activated in response to infection (34). Further characteriza-
tion of a large number of murine leukemia virus (MLV) and
HIV-1 integration sites have indicated that MLV is integrated
preferentially near the start of actively transcribed genes,
whereas HIV-1 shows a bias for integration in many places
within such genes but not in the transcriptional start region
(42). These data suggest that transcriptionally active chromatin
is favored for integration of HIV-1 and MLV DNAs and,
conversely, transcriptionally silent chromatin is disfavored; the
basis for this distinction is unknown. On the other hand, cell
culture experiments with avian sarcoma virus (ASV) have
shown that transcriptionally active DNA is not a preferred
target for integration, and transcriptional activity may be cor-
related with a decrease in integration for the DNA of this
retrovirus (41). A better understanding of the factors that
affect the integration target site selection of different retrovi-
ruses may make it possible to design safer and/or more appro-
priate retroviral vectors for gene therapy.
Studies with purified enzymes and DNA substrates have
failed to show any sequence specificity for target site selection
in vitro, but the integration site patterns exhibited by different
retroviral integrases with the same naked DNA target are not
identical (23, 35). Other experiments have shown that the
binding of certain proteins can either prevent integration by
blocking access to the target DNA or stimulate integration by
distorting the target DNA structure (1, 14, 22) such as by
bending (20, 26). In addition, experimental systems using
mononucleosome particles (28) or minichromosome targets of
core histone octamers and circular DNA (29, 30) have shown
that retroviral DNA integration occurs preferentially into
DNA that is wrapped around the nucleosome compared to
nucleosome-free linker DNA. A 10-bp periodicity for integra-
tion has been observed at sites where the major groove of the
target DNA is exposed on the face of the nucleosome. Inte-
grase proteins from different retroviral species can respond
differently to the changes in DNA structure caused by the
presence of nucleosomes (30). However, all of these earlier
studies have used open or uncompacted chromatin, leaving
unexplored the role played by higher-order chromatin struc-
ture in the retroviral integration process.
To investigate the role of chromatin structure in retroviral
DNA integration, we have asked how its compaction affects the
efficiency of integrase-mediated joining of viral sequences to
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target DNA, with a well-characterized reconstituted chromatin
substrate (Fig. 1A) (8, 37) and purified integrase proteins. Our
defined-length oligonucleosome target comprises an array of 13
phased nucleosomes, which accurately models the features of
native, extended chromatin, and contains binding sites for specific
transcription factors (8). The array is also sufficiently long to be
able to assume a compacted chromatin structure under appropri-
ate salt conditions or upon addition of linker histone H1. With
this system, we have uncovered unexpected differences in the
target preferences of integrase proteins from HIV-1 and ASV.
MATERIALS AND METHODS
Viral DNA substrates and PCR primers. A synthetic oligodeoxyribonucleotide
HIV-1 duplex substrate (21 bp) and an analogous ASV substrate (18 bp) were
FIG. 1. Control experiments to examine the influence of retroviral integration reaction conditions and components on nucleosome arrays.
(A) Diagram of the MluI-PvuII DNA fragment used to reconstitute the albumin (alb)-5S nucleosome arrays. The locations of the PCR target and
viral DNA primers are shown by arrows at the bottom. (B) Effects of integrase and integration reaction components of nucleosome arrays. DNase
I digestion analysis of extended nucleosome arrays in the presence of array buffer with (IN lanes) or without (Control lanes) ASV integration
reaction components. Lane E, partial EcoRI digest of a DNA end-labeled, extended nucleosome array. Positions of nucleosomes on reconstituted
arrays are indicated to right. (C) Effect of temperature and MgCl2 on nucleosome compaction and accessibility of HNF3. Lanes: 1, extended
nucleosome array; 2 to 9, array compacted with histone H1 in the absence () or presence () of HNF3; 2 and 3, incubation of the compacted
nucleosome array for 1 h at room temperature; 4 and 5, incubation at 37°C; 6 and 7, incubation with 1 mM MgCl2 at room temperature; 8 and
9, incubation with 1 mM MgCl2 at 37°C. The locations of the nucleosomes corresponding to the albumin enhancer and promoter N1, N2, and P
are indicated at the right. DNase I concentrations used: 4 g/ml for lane 1 and 8 g/ml for lanes 2 to 9. (D) Effects of viral DNA substrates and
viral integrases on nucleosome compaction and accessibility of HNF3. Lanes: 1, extended nucleosome array; 2 to 9, array compacted with histone
H1 in the absence () or presence () of HNF3 (the compacted nucleosome array was incubated for 1 h in lanes 2 and 3 with 1 mM MgCl2 and
ASV donor DNA at 37°C); 4 and 5, array compacted with 100 ng of soluble HIV-1 (sIN) integrase protein and HIV-1 donor DNA; 6 and 7, array
compacted with 50 ng of ASV integrase protein and ASV donor DNA; 8 and 9, array compacted with 200 ng of ASV integrase protein and ASV
donor DNA amounts similar to those in lanes 6 and 7. DNase I concentrations used: 4 g/ml for lane 1 and 8 g/ml for lanes 2 to 11.
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described previously (22). The single-stranded oligodeoxyribonucleotides were
purified by 20% polyacrylamide gel electrophoresis, and complements were
annealed at equimolar concentrations in TE buffer (10 mM Tris HCl, 1 mM
EDTA, pH 8.0) by heating to 95°C for 5 min, followed by slow cooling to room
temperature. Two fixed oligodeoxynucleotide primers complementary to target
DNA sequences were used for PCR-based detection of joining events. The target
primers were specific for regions upstream of the predicted positions of nucleo-
somes N1 and N2 in the albumin region, respectively (Fig. 1A) (25): 5-GCC
TAG AAA ATA ACC TGC GTT ACA-3 and 5-GGC AAC CCA CAC ATC
CTT AGG CAT-3. These target DNA primers were labeled at the 5 end with
[-32P]ATP and T4 polynucleotide kinase. The virus-specific primer for PCR-
based detection of HIV-1-mediated joining events was 5-GTG TGG AAA ATC
TCT AGC A-3, and that for detection of ASV-mediated joining was 5-ATT
GCA TAA GAC TA CA-3.
Nucleosomal array reconstitution. Core histones were purified from sheep
liver and used in nucleosome array assembly reaction mixtures containing 2 g
of a 32P-end-labeled double-stranded DNA fragment and core histones at an
approximately equal molar ratio of nucleosomal sites and octamers, as described
previously (8). Several assembly reaction mixtures containing a range of DNA-
histone concentrations were performed, and ideal array saturation (i.e., at a
molar ratio of 1:1.2) was determined by the EcoRI digestion assay (8).
Binding reactions, chromatin compaction, and DNase I assays. Binding reac-
tions for the in vitro integration and DNase I assays were carried out with a
nucleosome array concentration of 1 nM (1.5 ng/l) as previously described (8).
To prepare compacted nucleosome arrays, a mixture of 7.5 or 13 nM purified
histone H1 (Boehringer) and an extended nucleosome array concentration of 1
nM was incubated at room temperature for 1 h to obtain different degrees of
array compaction. For NaCl-mediated nucleosome array compaction, the final
NaCl concentration was 100 or 120 mM and the mixtures were incubated at room
temperature for 1 h. To achieve HNF3-mediated chromatin opening, the H1-
compacted array was incubated with 20 nM mouse HNF3 transcription factor
for 2 h at room temperature (8). The mouse HNF3 and GATA4 proteins were
purified from Escherichia coli (9, 43).
DNase I digestion was carried out as previously described (8). Briefly, the
reaction mixture included 2.5 to 10 g of DNase I per ml diluted in 50 mM
MgCl2, and incubation was at room temperature for 1 min. Digestions were
terminated by addition of an equal volume of stop buffer (20 mM Tris-HCl [pH
7.5], 50 mM EDTA, 1% sodium dodecyl sulfate, 0.2 mg of proteinase K per ml),
followed by incubation at 50°C for 30 min. Purified digestion products were
subjected to electrophoresis in 1% agarose–0.5 Tris-borate-EDTA gels. Gels
were fixed in 10% acetic acid–10% methanol and dried.
HIV-1 and ASV in vitro integration assays. Following incubation with histone
H1 or transcription factors as indicated, the volume of each mixture was in-
creased from 10 to 20 l by adding the integration reaction mixture. The final
concentrations of integration reaction components were 0.25 mg of bovine serum
albumin per ml, 6.4% glycerol, 5.7 mM dithiothreitol, 0.02% Nonidet P-40, 12
mM HEPES (pH 7.5), 45 mM KCl, and 0.1 mM MgCl2. Assays of ASV and
HIV-1 integrase activities were performed under conditions that were optimal
for each enzyme. ASV reaction mixtures included 50 ng (0.15 nM) of integrase,
1 pmol of ASV oligodeoxyribonucleotide duplex substrate (0.1 nM), and 1 mM
MgCl2; HIV-1 reaction mixtures contained 100 ng (0.3 nM) of integrase, 1 pmol
(0.1 nM) of HIV-1 oligodeoxyribonucleotide duplex substrate, and 1 mM MnCl2,
as the activity of this protein in MgCl2 is too low to detect any joining in this
assay. For HIV-1 integration assays, we used bacterially produced HIV-1sIN
integrase (NY5 strain sequence) that included the following amino acid substi-
tutions to improve solubility: C56S, C65S, W131D, F139D, F185H, and C280S
(40). The activity of this enzyme was comparable to that of the His-tagged HIV-1
wild-type version of this IN protein (HIV-1wt/His). Both derivatives display
wild-type processing and joining activities and can be stored and assayed at
relatively high concentrations.
Following incubation for 1 h at 37°C with ASV or HIV-1 integration compo-
nents, 10-l samples were removed for DNase I analysis. The remainder of the
reaction mixtures were deproteinized by increasing the volume to 130 l by addition
of EDTA (final concentration of 4.25 mM), sodium dodecyl sulfate (final concen-
tration of 0.44%), and proteinase K (final concentration of 0.06 mg/ml). After
digestion for 60 min at 37°C, the reaction mixtures were extracted with phenol,
followed by phenol-chloroform-isoamyl alcohol (25:24:1 mixture), and the DNA was
precipitated with ethanol. The DNA pellets were then dissolved in 10 l of water. As
the nucleosomal DNA was labeled with 32P at one end, concentrations of all samples
were estimated by analysis in a scintillation counter.
For both ASV and HIV-1 reaction mixtures, joining of viral DNA to specific
regions in the target was detected with a PCR-based assay. Equal amounts of the
DNA from a joining reaction were incubated with [-32P]dATP-labeled target
and viral DNA primers. PCR mixtures (50 l) contained 50 mM KCl, 20 mM
Tris-HCl buffer (pH 8.4), 5 mM MgCl2, 200 M deoxynucleoside triphosphate,
and 2 U of Taq polymerase (Gibco BRL). Reaction mixtures were cycled as
follows: 92°C for 3 min and 30 cycles of 92°C for 40 s, 50°C for 40 s, and 72°C for
45 s. PCR products were analyzed on 6% sequencing gels that included a 10-bp
ladder that was also 5 end labeled.
HIV-1wt/His integrase purification. Frozen resuspended cells expressing HIV-
1wt/His integrase, harvested from 2.4 liters of Luria broth culture, were thawed
and resuspended in lysis buffer (25 mM BisTris [pH 6.1], 1 M KCl, 1 M urea, 1%
thiodiglycol, 5 mM imidazole) at 0.13 g of cells/ml. Lysis was performed by
French press, followed by sonication for 30 s, and the preparation was then
subjected to centrifugation for 30 min at 30,000  g. The supernatant fraction
was filtered through a 0.22-m-pore-size filter and applied to a 5-ml HiTrap
iminodiacetic acid column freshly charged with 50 mM NiSO4 and equilibrated
with lysis buffer containing 10% glycerol. The column was washed with 20
column volumes of the equilibrating buffer, and bound protein was eluted with a
gradient of 5 mM to 1 M imidazole containing 25 mM BisTris (pH 6.1), 1 M KCl,
1 M urea, 1% thiodiglycol, and 10% glycerol. Fractions containing integrase were
pooled, EDTA was added to a final concentration of 0.5 mM, and the prepara-
tion was frozen in aliquots at 70°C.
Single aliquots of the IN preparation were thawed and diluted fourfold with 25
mM BIS-Tris (pH 6.1)–1 M urea–2 mM -mercaptoethanol–0.1 mM EDTA–
10% glycerol to reduce the KCl concentration to 0.25 M. This solution was
immediately applied to a 5-ml HiTrap heparin column equilibrated with 25 mM
BIS-Tris (pH 6.1)–0.25 M KCl–1 M urea–2 mM -mercaptoethanol–0.1 mM
EDTA–10% glycerol with a syringe. Following a wash step with the equilibrating
buffer, bound protein was eluted with a gradient to 1 M KCl. Fractions containing IN
were pooled, concentrated, and dialyzed against 25 mM BIS-Tris (pH 6.1)–0.5 M
KCl–1% thiodiglycol–1 mM dithiothreitol–0.1 mM EDTA–40% glycerol. After di-
alysis, the IN preparation was subjected to centrifugation at 30,000  g for 15 min
to remove any precipitated protein, and aliquots were frozen in liquid nitrogen.
RESULTS
Model chromatin substrate. To examine the influence of
higher-order chromatin structure on retroviral DNA integra-
tion in vitro, we used a 2,705-bp target DNA that can be
assembled into a phased array of 13 nucleosomes. This target
includes a trinucleosome-sized DNA section corresponding to
the albumin gene enhancer and promoter, flanked on either
side by five copies of a sea urchin 5S rRNA gene nucleosome
positioning sequence (Fig. 1A) (8). The presence of binding
sites for specific transcription factors in the albumin enhancer
region makes it possible to examine the effects of their binding
on retroviral DNA integration in vitro. Extended nucleosome
arrays were assembled from end-labeled DNA templates and
purified core histones. The nucleosomal DNA migrated faster
on an agarose gel than did the naked DNA, as expected, and
digestion of the extended array with EcoRI restriction endo-
nuclease yielded less than 5% free DNA in this preparation
(data not shown; see also references 2, 16, and 39). Partial
digestion of the arrays with DNase I revealed cleavages and
protections indicative of 13 evenly spaced nucleosomes (Fig.
1B, lanes 7 to 9). As a control for stability under our assay
conditions, the extended nucleosome arrays first were incu-
bated with components of the integration reaction mixture
(purified ASV integrase protein, viral donor DNA, 1 mM
MgCl2) at 37°C for 1 h. Partial digestion with DNase I showed
that none of these components or the incubation temperature
caused any change in the nucleosomal digestion pattern (Fig.
1B, lanes 10 to 12). Naked target DNA was used as a control
for DNase I activity in the presence of integration reaction
mixture components (Fig. 1B, lanes 1 to 5). The greater extent
of digestion of the extended nucleosome array in the presence
of the integration reaction mixture components is the result of
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more favorable conditions for DNase I rather than an effect on
the array (compare lanes 9 and 12 and lanes 3 and 5). Similar
control experiments with HIV-1 integration reaction mixture
components also failed to show any effect on DNase I digestion
patterns of the extended nucleosome array (data not included).
The extended arrays were then compacted by addition of the
linker histone H1 to nucleosomes at a 1:1 molar ratio. As
illustrated in Fig. 1C (compare lanes 1 and 2), compaction with
H1 rendered the arrays virtually resistant to the same concen-
tration of DNase I (8 g/ml) that is able to digest the extended
array almost completely (Fig. 1B, lane 12). As expected from
previous studies (8), addition of the transcription factor HNF3
increased DNase I sensitivity in the vicinity of its binding site in
the DNA of nucleosome N1 (Fig. 1C and the diagram in Fig.
2B). Addition of the HIV-1 integration reaction mixture com-
ponents at the standard incubation temperature (37°C) had no
effect on nucleosome compaction or chromatin opening by
HNF3 as measured by DNase I digestion (Fig. 1D, lanes 4 and 5).
Similar results were observed upon addition of 50 ng of ASV
integrase, our standard condition (Fig. 1D, lanes 6 and 7). How-
ever, upon addition of a larger amount of protein (200 ng), with
the same donor DNA concentration, DNase I digestion was to-
tally inhibited (Fig. 1D, lanes 8 and 9). It is possible that at this
high protein concentration, the binding of ASV integrase to the
chromatin target blocks access to the DNase I (6).
Transcription factors HNF3 and GATA4 block the integra-
tion of viral DNA at their binding sites in the extended nu-
cleosome array. To detect joining of the viral DNA sequences
to the target DNA by purified retroviral integrase, we used a
PCR-based assay with a labeled primer similar to that de-
scribed previously (7, 22, 30). The size of the PCR product
reflects the distance between the joining site and a fixed point
in the target DNA. We used two primers, complementary to
different regions in the target DNA, to monitor viral donor
DNA joining to DNA associated with nucleosome N2 or N1
and the upstream linker region (Fig. 1A, bottom section).
Comparable viral DNA joining patterns were observed with
the different primer sets (data not shown), confirming the
validity of the assay. Several control experiments (data not
shown) were carried out to verify that a PCR product was gen-
erated only when integrase and the cognate donor viral DNA
were present. No PCR product was detected in the presence of
EDTA or if the joining reaction mixtures were left on ice.
Patterns of integrase-mediated joining to naked DNA and
FIG. 2. Retroviral integrase-mediated joining to the extended nucleosome array. (A) Controls for the retroviral integration reaction. Lanes: 1 and 2,
ASV integrase-mediated joining of the cognate viral donor DNA to the naked target (DNA) and to the extended nucleosome array (ExNA) (dots mark
the 10-bp periodicity for joining); 4 and 5, HIV-1sIN-mediated joining of the cognate viral donor DNA to the naked target and extended nucleosome
array; 7 and 8, HIV-1wt/His integrase-mediated joining of the cognate viral donor DNA to the naked target and extended nucleosome array; 3 and 6,
10-bp DNA molecular weight marker (M). The position of the N2 nucleosome is shown at the left. (B) Sites of HNF3 and GATA4 binding to the
nucleosome N1 region in the albumin enhancer region. The position of the nucleosome is indicated by the oval. Labeled boxes indicate transcription
factor binding sites. (C) ASV DNA joining is blocked at sites at which transcription factor GATA4 is bound to the nucleosome array. Lanes: 1, 10-bp
DNA molecular weight marker (M); 2, ASV DNA joining after incubation at 0°C; 3, ASV DNA joining after incubation at 37°C; 4, ASV DNA joining
after incubation at 37°C after preincubation in 20 nM GATA4; 5, ASV DNA joining after incubation after preincubation in 40 nM GATA4. The GATA4
binding site is designated eF. Arrows show sites of target DNA protection (footprinting) from ASV DNA joining. (D) ASV DNA joining is blocked at
sites at which transcription factor HNF3 is bound to the nucleosome array. Lanes: 1, ASV DNA joining to a nucleosome array at 37°C; 2, ASV DNA
joining to a nucleosome array preincubated with 20 nM HNF3; 3, ASV DNA joining to a nucleosome array preincubated with 40 nM HNF3. HNF3
binding sites are designated NS-A1, eG, and eH. Arrows show sites of target DNA protection (footprinting) from ASV DNA joining.
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the extended nucleosome array in the N2 region are shown in
Fig. 2A. As expected (23, 35), different patterns were observed
in the same naked DNA targets with ASV and HIV-1 inte-
grases, with some sites preferred by one system and not the
other. However, both enzymes produced a noticeable 10-bp
periodicity for joining in the extended nucleosome array target
(ExNA, Fig. 2A, lanes 2, 5, and 8), as has been reported
previously for the MLV and HIV-1 integrases (30). We found
that the joining patterns for the HIV-1sIN and HIV-1wt/His
integrases are indistinguishable (compare lanes 4 and 7 and
lanes 5 and 8), indicating that the solubility-improving substi-
tutions do not affect the integration preferences. We next
asked if the binding of transcription factors to the extended
nucleosome array would affect the joining reaction. As illus-
trated in Fig. 2B, the HNF3 transcription factor is known to
bind specifically to its sites, designated eG, eH, and NS, in the
N1 nucleosome of the extended array in vitro and forms pro-
tected and hypersensitive sites, as detected by DNase I foot-
FIG. 3. Influence of target nucleosome array compaction on integrase-mediated joining of viral DNAs. (A) Experimental design. The extended
nucleosome array was incubated with increasing amounts of histone H1 for 1 h, followed by addition of the ASV or HIV-1 integration components.
One hour later, the mixture was analyzed by DNase I assay and by PCR with the N2-specific target DNA primer and an HIV-1 or ASV donor DNA
primer. (B) DNase I analysis of the target DNA after incubation with the ASV DNA joining components (on the left) and PCR detection of the
ASV DNA joining pattern (on the right). NA, extended nucleosome array. On the left side, DNase I concentrations are shown above the gel. Right
side: lane 1, naked DNA target; lane 2, extended nucleosome array without histone H1; lane 3, array compacted by addition of 7.5 nM histone
H1; lane 4, extended array compacted by addition of 13 nM histone H1. (C) DNase I analysis of the DNA used as a target for HIV-1 DNA joining
(on the left) and PCR detection of the HIV-1 DNA joining pattern (on the right). DNase I concentrations used (left side, 4 g/ml for lane 1 and
8 g/ml for lanes 2 and 3). Right side: lanes 1 to 3, HIV-1sIN-mediated DNA joining; lanes 5 to 7, HIV-1wt/His IN-mediated DNA joining; lanes
1 and 5, extended nucleosome array; lanes 2 and 6, extended array compacted by addition of 7.5 nM histone H1; lanes 3 and 7, extended array
compacted by addition of 13 nM histone H1; lane 4, 10-bp molecular weight marker (M). (D) ASV integrase-mediated joining into NaCl-mediated
compacted targets. Naked DNA or the extended nucleosome array was incubated with 100 mM NaCl (lanes 2 and 5, respectively) or 120 mM NaCl
(lanes 3 and 6, respectively) and then incubated with the ASV integration components. Lanes 1 and 4, ASV DNA joining to naked DNA and the
extended nucleosome array in the presence of control buffer; lane 7, 10-bp molecular weight marker (M). (E) Comparison of ASV integration
patterns in the region of nucleosome N1 with extended and compacted nucleosomal arrays. The sequencing gels of panels B, right side, lanes 2
and 4 (top tracing), and D, lanes 4 and 6 (bottom tracing), were scanned with a Fuji BAS-250 Bio-imaging analyzer and analyzed with Image Gauge
4.0 software. Tick marks on the x axis correspond to the 10-bp DNA molecular weight marker.
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printing (8). The GATA4 transcription factor also binds at this
location, at a site designated eF (Fig. 2B) (8). As illustrated in
Fig. 2C, the presence of GATA4 inhibited ASV integrase-
mediated joining of viral DNA to the binding site of this factor
in the extended nucleosome array, as demonstrated by the loss
of specific integration products in the N1 region (footprinting;
see arrows). Similar results were observed for HNF3; ASV
integrase-mediated joining of donor viral DNA was blocked at
the eG, eH, and NS binding sites of N1 in the target DNA (Fig.
2D). No other changes in integration patterns were detected.
Specifically, no preferred sites for joining were generated in
the presence of these factors. From these data, we conclude that
GATA4 and HNF3 transcription factor binding to the extended
nucleosomal array limits access to their binding sites for the in-
tegration machinery, as expected from previous studies with na-
ked DNA targets (1, 14, 22). This result is similar to the inhibition
of DNase I cleavage in footprinting experiments (3, 36), with
some pattern variations likely due to differences in the way IN and
DNase I act on a nucleosomal target; integrase joins viral DNA to
target DNA at exposed sites on the major groove (30), whereas
DNase I cleaves the target DNA in the minor groove (38).
Integration of viral donor DNA into the H1-compacted nu-
cleosome array. To study the influence of higher-order chro-
matin structure on the efficiency of retroviral integration, the
extended nucleosome array target was compacted with linker
histone H1 (Fig. 3A). After the integration reactions were
terminated, one-half of the mixture was analyzed by DNase I
digestion, which served as a control to measure the reduced
accessibility caused by histone H1-mediated compaction (e.g.,
Fig. 3B, left side). The other half of the mixture was incubated
with proteinase K, followed by DNA purification, and viral
DNA joining in the N1 region was detected by PCR (e.g., Fig.
3B, right side). Results obtained with the ASV integration
system again showed that the pattern obtained with naked
DNA was distinct from that observed with the extended nu-
cleosome array (Fig. 3B, right side, compare lanes 1 and 2).
Remarkably, the efficiency of joining increased substantially
upon compaction of the array with histone H1 (compare lanes
2 and 3). Further compaction by histone H1 did not change the
integration pattern but appeared to increase the efficiency of
joining (compare lanes 2 and 4). In three independent exper-
iments, we observed a more-than-sevenfold increase in ASV
joining to targets compacted by 13 nM histone H1 compared to
the extended array, on the basis of density scanning. This
increase in efficiency with the compacted target was not uni-
form; some sites in the target were preferred over others for
joining of viral DNA.
As shown in Fig. 3C (left side), reduced target DNA acces-
sibility due to histone H1-mediated compaction was again ver-
ified by DNase I digestion of the reaction mixture incubated
with HIV-1 integration components. However, in sharp con-
trast to the results obtained with ASV, no increase in the
efficiency of the donor viral DNA joining was observed with
either the soluble derivative, sIN, or wt HIV-1 integrase in the
presence of histone H1 (Fig. 3C, right side, compare lanes 1
and 2 and lanes 5 and 6). Furthermore, the efficiency of joining
by the HIV-1 integrases actually decreased with increased con-
centration of histone H1 (compare lanes 2 and 3 and lanes 6 and
7). The similar behaviors of the two HIV-1 integrases indicate
that differences observed in the integration preferences of the
ASV and HIV-1 proteins are not due to the solubility-improving
substitutions. The inhibition of HIV-1 integrase-mediated joining
by chromatin compaction highlights the specificity of the en-
hanced joining observed with ASV integrase.
We considered the possibility that the observed ASV inte-
grase-mediated increase in joining of viral donor DNA se-
quences to the compacted target DNA might be the result of
interaction of this integrase protein with linker histone H1.
Alternatively, this result could be due to an ASV integrase-
specific preference for a compacted DNA target. To distin-
guish between these two possibilities, we used an H1-indepen-
dent method of compaction; the extended nucleosome array
was incubated in the presence of 100 or 120 mM NaCl for 1 h
to produce salt-dependent compaction (15; also see Fig. 1F in
reference 8). It was reported previously that variation in the
monovalent-ion concentration within this range has no signif-
icant effect on the efficiency of the ASV integration reaction
(12). As shown in Fig. 3D (lanes 1 and 2), under our condi-
tions, 100 mM NaCl had a slight inhibitory effect on the effi-
ciency of ASV integrase-mediated joining to naked target
DNA. On the other hand, increased efficiency of joining to the
nucleosome array was observed at this NaCl concentration,
similar to that observed in the same region with histone H1
compaction (Fig. 3B, right side). This effect was even more
FIG. 4. ASV integrase-mediated joining of viral DNA to the com-
pacted array opened locally by the HNF3 transcription factor. The
histone H1-compacted nucleosome array was incubated for 2 h with
transcription factor HNF3, and then the ASV integration components
were added. One hour later, the mixture was analyzed by DNase I
assay and by PCR with N1-specific target DNA and ASV donor DNA
primers. DNase I analysis is shown in the left-side DNA. Lanes: 1,
extended array; 2, extended array compacted by 7.5 nM histone H1; 3,
7.5 nM histone H1-compacted array opened locally by HNF3; 4, ex-
tended array compacted by 13 nM histone H1; 5, 13 nM histone
H1-compacted array opened locally by HNF3. The DNase I concen-
trations used were 4 g/ml for lane 1 and 8 g/ml for lanes 2 to 5.
Results from the joining assay are on the right side. Lanes:1, 10-bp
marker; 2, viral DNA joining to the extended nucleosome array; 3 and
4, DNA joining to the extended nucleosome array compacted with 7.5
nM histone H1 in the absence () or presence () of HNF3; 5 and 6,
with 13 nM histone H1 in the absence () or presence () of HNF3.
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striking in the presence of a higher salt concentration (120 mM
NaCl; Fig. 3D, lane 6), even though these conditions were
suboptimal for ASV integrase (Fig. 3D, compare lanes 1 and
3). We conclude that NaCl-compacted nucleosomal DNA is
also a preferred target for ASV integrase-mediated joining.
Figure 3E shows results from density scans of the data in
panels B (lanes 2 and 4) and D (lanes 4 and 6). This compar-
ison highlights the similarity in the patterns of ASV joining
with extended arrays (open traces) and arrays compacted by
either histone H1 or NaCl (shaded traces). Comparison of
these traces provides a quantitative estimate of the increased
efficiency of joining to the chromatin compacted by either
method. It appears from these results that the compacted
DNA structure, rather than an interaction with histone H1 per
se, enhances this reaction.
Unfortunately, parallel experiments with the HIV-1 integra-
tion components were not possible, as the HIV-1 integration
reaction was completely inhibited in the presence of 100 mM
NaCl with both naked DNA and compacted nucleosome tar-
gets.
HNF3 binding to the compacted nucleosome array has no
effect on ASV integrase-mediated joining. As illustrated in Fig.
1C and D, binding of transcription factor HNF3 to the histone
H1-compacted array creates a DNase I-sensitive site in the
vicinity of binding. To determine if this change creates a pre-
ferred or restricted site for integration, we added HNF3 to the
H1-compacted nucleosome array and then incubated this sub-
strate with ASV integration components. As a control, half of
the incubation mixture was again analyzed by the DNase I
digestion assay, as outlined in Fig. 3A, to verify that the target
was compacted and HNF3 was bound at the expected site (Fig.
4, left side). As shown in Fig. 4 (right side), an increase in the
efficiency of ASV-mediated joining was again observed with
increasing nucleosome array compaction. However, the pat-
tern of joining in the vicinity of the HNF3 binding site was
unaffected by the presence of this transcription factor. Thus,
locally open chromatin was not a preferred integration target
in the compacted array.
DISCUSSION
In these in vitro studies of retroviral DNA integration, we
took advantage of a DNA target that has been used previously
to reconstitute extended nucleosome arrays that can be com-
pacted into higher-order structures comparable to chromatin
in living cells (8). Our results showed that when an extended
nucleosomal array is used as an integration target by ASV and
HIV-1 integrases, the distribution of joining sites is distinct
from that observed in the corresponding naked DNA, consis-
tent with earlier findings (30). However, further compaction of
the extended array by histone H1 or a high NaCl concentration
did not cause major changes in the joining pattern but had
dramatically opposite effects on the efficiency of the reaction
with the ASV and HIV-1 integrases. We found that ASV
integrase-mediated joining of the cognate viral DNA was sub-
stantially more efficient with a histone H1-compacted DNA
chromatin target than with naked DNA or an extended nu-
cleosome array. A similar increase was also observed with
NaCl-compacted target chromatin, suggesting a critical role for
the structure of the DNA in compacted chromatin, rather than
interactions between the ASV integration machinery and his-
tone H1. In contrast to the results obtained with ASV inte-
grase, a decrease rather than enhancement of integration into
the histone H1-compacted chromatin target was observed in
reactions catalyzed by HIV-1 integrase. These observations
indicate that the integration machineries of these two retrovi-
ruses may be markedly different in their site selection prefer-
ences.
Extended chromatin and compacted chromatin are charac-
teristic of actively transcribed or silent regions of cellular chro-
mosomes, respectively. Actively transcribed regions include a
number of bound components that could potentially reduce
the efficiency of retroviral DNA integration. Our data suggest
that transcription factors bound to the chromatin may block
ASV DNA integration in actively transcribed regions. The
HNF3 transcription factor binds to three sites in the DNA
associated with nucleosome N1 in the extended nucleosome
array, and such binding results in DNA protection and expo-
sure of hypersensitive sites, as detected by DNase I footprint-
ing (8). In our ASV integrase-mediated joining reaction, ac-
cessibility was limited specifically at HNF3 binding sites in this
target DNA but, interestingly, we did not observe any addi-
tional hot spots for viral donor DNA joining in the presence of
this transcription factor. We also asked if HNF3 transcription
factor binding to the histone H1-compacted target would affect
ASV integrase-mediated joining in our system. Surprisingly,
we observed no changes in the joining pattern when the com-
pacted target was opened by HNF3 binding, even though our
control experiment showed that sequences in the N1 nucleo-
some region became more accessible to DNase I digestion.
These results underscore the preference of ASV for com-
pacted chromatin, even when an open region is available on
the same template.
The striking differences we observed between the target
preferences of the ASV and HIV-1 integrases suggest that
these proteins may interact differentially with extended and
compacted chromatin in vivo. Although many factors may con-
tribute to target site selection (11, 33), it is noteworthy that the
joining preferences of the integrase proteins that we have un-
covered in vitro are consistent with results reported for inte-
gration of ASV and HIV-1 DNAs in infected cells (34, 41).
This observation underscores the importance of using more
developed models of chromatin structure in vitro to replicate
integration activities seen in vivo.
Retroviral integration site selection has become an impor-
tant topic of study owing to the use of retroviral vectors in gene
therapy for human disease. Several cases of insertional mu-
tagenesis, believed to have been triggered by integration of the
MLV vector DNA near the growth-promoting gene LMO2
were recently observed. In these clinical studies, 2 of 11 pa-
tients treated for severe combined immunodeficiency disease
developed leukemias, with the malignant cells showing inte-
grations at this locus (4, 5). A recent study with mice has also
shown that integration of replication-deficient MLV vector
DNA is associated with leukemia development (24). Our re-
sults suggest that an ASV vector might have some advantage
over MLV or HIV-1 vectors if integration into actively tran-
scribed regions is to be avoided. On the other hand, integration
into regions of compacted chromatin might cause silencing of
an integrated ASV vector. Additional engineering, for exam-
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ple, introduction of insulator sequences, might help to alleviate
this problem (10, 18, 31). As ASV has in common with HIV-1
the ability to infect nondividing cells (17, 21), an ASV vector
may be especially useful for particular therapeutic applica-
tions.
Integrases from different retroviruses produce unique and
reproducible patterns of integration into naked DNA in vitro.
The determinants for these patterns appear to be located
within the core domain of the protein (19, 23, 35). Here we
show that the HIV-1 and ASV integrases also have different
integration preferences with respect to compacted chromatin
targets. The molecular determinants for these properties of
integrases remain to be determined. Detailed knowledge about
the mechanism of integration site selection in chromatin may
contribute to the development of safer gene therapeutic tools.
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